Senti Biosciences Holdings Inc. (SNTI), a clinical-stage biotechnology company, on Thursday announced its first quarter financial results, and highlighted various business developments.
The company is developing SENTI-202 for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Q1 2026:
Net losses amounted to $4.22 million, or $0.14 per share, while in the same period in the prior year, the net loss was $14.11 million, or $1.41 per share.
Research and development (R&D) expenses were $5.3 million, relatively higher than the $3.9 million reported in the previous year.
Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $8.93 million.
Senti entered a security purchase agreement with an affiliate of Celadon Partners SPV 24, which may result in gross proceeds of $40 million aggregate in senior secured convertible notes. The company is also eligible to receive up to $60 million in milestone payments during the development of SENTI-202.
Business Updates:
The company is developing SENTI-202, a CAR-NK cell therapy targeting hematological malignancies. The drug previously received an orphan drug and regenerative medicine advancement therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA). Following a Type B Initial Comprehensive Multidisciplinary RMAT meeting, the company stated that it had completed the chemistry, manufacturing, and controls (CMC) requirements to advance the pivotal Phase 1 single-arm, multi-center trial in refractory or relapsed (R/R) AML with SENTI-202 administered after LD chemotherapy.
Enrollment is ongoing in the Phase 1 trial.
SNTI is currently trading at $1.04, up 8%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.